Analysis method and analysis device for mixing uniformity of medicinal preparation and medium
The calculation of the mixing uniformity of drug preparations through Raman spectroscopy technology solves the problems of complex monitoring and high operation requirements in the prior art, and achieves rapid and accurate monitoring of the mixing uniformity of drug preparations, improving bioavailability and efficacy.
Patent Information
- Application Number
- CN202411176084.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-12
AI Technical Summary
In the prior art, the monitoring of mixing uniformity of drug preparations is not easy to achieve, the operation is complicated, and the operator requirements are high. In vitro dissolution test and in vivo bioequivalence test are cumbersome and time-consuming, making it difficult to use for quality control in daily production. .
Raman spectroscopy technology is used to obtain the spectral data of a single dose of drug to be tested, and the mixing uniformity is calculated by the similarity value, standard deviation and preset coefficient value, simplifying the operation process, and providing an analysis method and analysis device for mixing uniformity of drug preparations and media to achieve fast and accurate mixing uniformity monitoring.
It improves the accuracy and simplicity of monitoring of mixing uniformity of drug preparations, reduces the technical requirements for operators, is more suitable for daily production and quality control than traditional methods, and improves the bioavailability and efficacy of drugs.
Smart Images

Figure CN118937307A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of drug analysis, and more specifically, to an analysis method, an analysis device and a medium for analyzing the mixing uniformity of a drug preparation. Background Art
[0002] Methods for testing drug preparations include in vitro dissolution test methods and in vivo bioequivalence tests. However, both in vitro dissolution test methods and in vivo bioequivalence tests are cumbersome and time-consuming, and in vitro dissolution tests and in vivo bioequivalence tests are not easy to implement for quality control in the daily production process.
[0003] Solid preparations are the most commonly used drug dosage forms, accounting for about 70% of all drug dosage forms. The preparation process of solid preparations includes the process of uniformly mixing raw materials and excipients. If the process is unstable or imperfect, it is likely to cause large differences in the content of active ingredients in individual products. In particular, after the preparations have undergone granulation and compression processes, the fluidity and density distribution of the materials may cause uneven unit doses. Whether the distribution of solid preparation components is uniform and stable will affect its disintegration and dissolution rate in the body, and then affect the bioavailability of the drug in the body, that is, affect the efficacy of the drug.
[0004] Drug preparations with the same raw materials, strict particle size control, and uniform mixing are more conducive to uniform release and full absorption by the human body, and have higher bioavailability. At present, the methods for measuring the mixing uniformity of drug preparations include near-infrared online quantitative monitoring technology and near-infrared chemical imaging technology, which are applied to the research and development and production links of the entire life cycle of drugs, and have high requirements on the professional technical ability of analytical operators and data analysis and processing capabilities. Summary of the invention
[0005] The present application is provided to solve the above defects existing in the prior art. An analysis method, an analysis device and a medium for the mixing uniformity of a pharmaceutical preparation are needed, and an accurate analysis method for the mixing uniformity of a pharmaceutical preparation is provided, which can solve the problems that the monitoring of the mixing uniformity is not easy to achieve, the operation is complicated and the requirements for the operator are high.
[0006] In a first aspect of the present application, a method for analyzing the mixing uniformity of a pharmaceutical preparation is provided, the method comprising: Acquire first Raman spectrum data of each single dose of a first number of single doses of a drug to be tested, each single dose of a drug to be tested satisfies a first condition, wherein the first condition includes that each single dose of a drug to be tested belongs to the same drug variety, has the same source, and has the same specification and batch number; Based on the first Raman spectrum data and the standard spectrum data, a similarity value corresponding to each single dose of the drug to be tested is obtained, and a first average similarity value is obtained, wherein the standard spectrum data is the Raman spectrum data of any single dose of the drug to be tested other than the first quantity; Obtaining a first standard deviation based on the first average similarity value and the first Raman spectrum data of each single dose of the drug to be tested; Determining an acceptable standard deviation coefficient value corresponding to the first quantity based on the value of the first quantity and a preset coefficient value correspondence table; Obtaining a first mixed uniformity calculation value based on the first average similarity value, the first standard deviation, and an acceptable standard deviation coefficient value corresponding to the first quantity; When the first calculated mixing uniformity value is less than or equal to a preset acceptable threshold, it is determined that the mixing uniformity of the single dose of the drug to be tested is acceptable.
[0007] In a second aspect of the present application, a device for analyzing the mixing uniformity of a drug preparation is provided, the device comprising a Raman spectrometer and a processing module, the Raman spectrometer being used to collect first Raman spectrum data of each of a first number of single doses of a drug to be tested; the processing module being configured to: Acquire first Raman spectrum data of each single dose of a first number of single doses of a drug to be tested, each single dose of a drug to be tested satisfies a first condition, wherein the first condition includes that each single dose of a drug to be tested belongs to the same drug variety, has the same source, and has the same specification and batch number; Based on the first Raman spectrum data and the standard spectrum data, a similarity value corresponding to each single dose of the drug to be tested is obtained, and a first average similarity value is obtained, wherein the standard spectrum data is the Raman spectrum data of any single dose of the drug to be tested other than the first quantity; Obtaining a first standard deviation based on the first average similarity value and the first Raman spectrum data of each single dose of the drug to be tested; Determining an acceptable standard deviation coefficient value corresponding to the first quantity based on the value of the first quantity and a preset coefficient value correspondence table; Obtaining a first mixed uniformity calculation value based on the first average similarity value, the first standard deviation, and an acceptable standard deviation coefficient value corresponding to the first quantity; When the first calculated mixing uniformity value is less than or equal to a preset acceptable threshold, it is determined that the mixing uniformity of the single dose of the drug to be tested is acceptable.
[0008] In a third aspect of the present application, a non-transitory computer-readable medium is provided, on which instructions are stored. When executed by a processor, the instructions execute the steps of the method for analyzing the mixing uniformity of a pharmaceutical preparation as described in any embodiment of the present application.
[0009] The analysis method, analysis device and medium for the mixing uniformity of drug preparations provided in each embodiment of the present application first obtain a similarity value based on the acquired Raman spectral data, then obtain a standard deviation, and then obtain a standard deviation coefficient according to a preset corresponding table, and then calculate to obtain a calculated value of the mixing uniformity, and make a judgment according to a preset threshold value. The entire processing process does not require the operator to perform complex operations, and only needs to obtain the Raman spectral data of each single dose of the drug to obtain the output result, which can solve the problems of difficult to implement monitoring of mixing uniformity, complex operation and high requirements on operators; in addition, the analysis method of the present application has been calibrated, has high accuracy, and is highly usable for different types of drug preparations. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] In the drawings, which are not necessarily drawn to scale, the same reference numerals may describe similar parts in different views. The same reference numerals with letter suffixes or different letter suffixes may represent different instances of similar parts. The accompanying drawings generally illustrate various embodiments by way of example and not limitation, and together with the specification and claims, are used to illustrate the embodiments applied for. When appropriate, the same reference numerals are used throughout the drawings to refer to the same or similar parts. Such embodiments are illustrative and are not intended to be exhaustive or exclusive embodiments of the present apparatus or method.
[0011] Figure 1 A flow chart showing a method for analyzing the mixing uniformity of a pharmaceutical preparation according to the first embodiment of the present application.
[0012] Figure 2 A flow chart showing a method for analyzing the mixing uniformity of a pharmaceutical preparation according to a second embodiment of the present application.
[0013] Figure 3 A box plot of variety thresholds of an embodiment of the present application is shown.
[0014] Figure 4 A schematic diagram showing the structure of a device for analyzing the mixing uniformity of a drug preparation according to an embodiment of the present application. DETAILED DESCRIPTION
[0015] In order to enable those skilled in the art to better understand the technical solution of the present application, the present application is described in detail below in conjunction with the accompanying drawings and specific implementation examples. The embodiments of the present application are further described in detail below in conjunction with the accompanying drawings and specific implementation examples, but are not intended to limit the present application.
[0016] The words "first", "second" and similar words used in this application do not indicate any order, quantity or importance, but are only used to distinguish. The words "include" or "comprise" and similar words mean that the elements before the word include the elements listed after the word, and do not exclude the possibility of including other elements.
[0017] According to an embodiment of the present application, a method for analyzing the mixing uniformity of a pharmaceutical preparation is provided, and the method comprises the following steps. Figure 1 A flow chart of a method for analyzing the mixing uniformity of a drug preparation according to a first embodiment of the present application is shown. In step 101, first Raman spectrum data of each of a first number of single doses of a drug to be tested is obtained, and each single dose of a drug to be tested satisfies a first condition, wherein each single dose of a drug to be tested belongs to the same drug variety, has the same source, and has the same specification and batch number.
[0018] The weight of the main drug component in a single-dose drug is relatively large (for example, the weight ratio exceeds 80%). The single-dose drug to be tested is a single-dose drug to be tested, such as acetaminophen tablets. The single-dose drug is pretreated before the Raman spectrometer is used to obtain Raman spectral data. The pretreatment includes grinding the drug. After grinding, the tablet drug can expose the tablet core, and the capsule drug can expose the contents to obtain accurate Raman spectral data.
[0019] The first condition includes that each single dose of the drug to be tested belongs to the same drug variety, has the same source, and has the same specification and batch number. That is, each single dose of the drug to be tested belongs to the same variety, the same manufacturer, the same specification and the same batch number.
[0020] In step 102, based on the first Raman spectrum data and standard spectrum data, similarity values corresponding to each single dose of the drug to be tested are obtained, and a first average similarity value is obtained, wherein the standard spectrum data is Raman spectrum data of any single dose of the drug to be tested other than the first quantity.
[0021] For example, 11 single-dose drugs to be tested are selected, of which 10 are the first number of single-dose drugs to be tested, and the 11th single-dose drug to be tested corresponding to the standard spectrum data can be optional. The standard spectrum data can be obtained and stored first. The similarity coefficient method can be used to obtain a similarity value based on the first Raman spectrum data and the standard spectrum data.
[0022] In step 103, a first standard deviation is obtained based on the first average similarity value and the first Raman spectrum data of each single dose of the drug to be tested. The standard deviation calculation formula can be used for calculation. The standard deviation formula is: .
[0023] In step 104, based on the value of the first quantity and a preset coefficient value correspondence table, an acceptable standard deviation coefficient value corresponding to the first quantity is determined. The following Table 1 is used as an example for description.
[0024] Table 1 k and k for different sample sizes n R value In the above table, n represents the value of the first quantity, and k represents the acceptable standard deviation coefficient value. Therefore, the corresponding acceptable standard deviation coefficient value can be obtained by looking up the table.
[0025] In step 105, a first mixed uniformity calculation value is obtained based on the first average similarity value, the first standard deviation and the acceptable standard deviation coefficient value corresponding to the first quantity. The first mixed uniformity calculation value can be obtained based on the mixed uniformity calculation formula.
[0026] In some embodiments, based on the first average similarity value, the first standard deviation and the acceptable standard deviation coefficient value corresponding to the first quantity, a first mixed uniformity calculation value is obtained, including: using formula (1) to calculate the first mixed uniformity calculation value, the formula (1) is: A=(M- )+kS(1) Wherein, A is the calculated value of mixing uniformity; M is the reference value of mixing uniformity; is the average similarity value; k is the acceptable standard deviation coefficient; S is the standard deviation. The M value can be taken as 1.
[0027] In step 106, when the first mixed uniformity calculated value is less than or equal to a preset acceptable threshold, it is determined that the mixed uniformity of the single dose of the drug to be tested is acceptable. The acceptable threshold may be preset based on an acceptable pass rate or the like.
[0028] Through the above steps, the degree of uniform mixing of the active ingredients in a single dose of medicine can be determined without the need for operators to perform more complicated operations. It is simple and easy to implement and has a wider application than in vivo bioequivalence tests and in vitro dissolution tests. The analytical method of the present application has high accuracy, which is conducive to accurately analyzing the component distribution of a single dose of medicine, and then used to evaluate the drug product. It can also be used for online monitoring of drug mixing uniformity during the production process.
[0029] In some embodiments, when the first mixed uniformity calculation value is greater than a preset acceptable threshold, an unacceptable standard deviation coefficient value corresponding to the first quantity is determined based on a corresponding table of values of the first quantity and preset coefficient values; a second mixed uniformity calculation value is obtained based on the first average similarity value, the first standard deviation and the unacceptable standard deviation coefficient value; when the second mixed uniformity calculation value is greater than a preset acceptable threshold, it is determined that there is a risk in the mixing uniformity of the single dose of drug to be tested.
[0030] As shown in Table 1, taking L (acceptable threshold) = 0.06 and n = 10 as an example, when A (the first mixed uniformity calculation value) obtained by formula 1 is ≤ 0.06, the mixed uniformity of the single dose of the drug to be tested is considered acceptable, that is, it can be considered to be within the qualified range. If A (the first mixed uniformity calculation value) > 0.06, it is considered that there is a risk in the mixed uniformity of the single dose of the drug to be tested, and k corresponding to n = 10 is obtained using Table 1. R =1.55, then use k R Substituting into formula (1) to obtain the corresponding A value (the second mixed uniformity calculated value), if the A value (the second mixed uniformity calculated value) is still greater than 0.06, it is considered that the mixed uniformity of the single dose of the drug to be tested does have a risk. In this way, the detection accuracy of the mixed uniformity of the single dose of the drug can be greatly improved.
[0031] In some embodiments, when the second mixed uniformity calculation value is less than or equal to a preset acceptable threshold, the following steps are performed. Figure 2 A flow chart of the method for analyzing the mixing uniformity of a pharmaceutical preparation according to the second embodiment of the present application is shown. In step 201, the second Raman spectrum data of each single dose of the single dose of the drug to be tested of the second number of single doses of the drug to be tested is obtained, and the second number is greater than the first number. In step 202, based on the first Raman spectrum data and the second Raman spectrum data and the standard spectrum data, the similarity values corresponding to each single dose of the drug to be tested are obtained, and the second average similarity value is obtained. In step 203, based on the second average similarity value and the first Raman spectrum data and the second Raman spectrum data of each single dose of the drug to be tested, the second standard deviation is obtained. In step 204, based on the value of the sum of the second number and the first number and the preset coefficient value corresponding table, the acceptable standard deviation coefficient value corresponding to the sum of the second number and the first number is determined. In step 205, based on the second average similarity value, the second standard deviation, and the acceptable standard deviation coefficient value corresponding to the sum of the second number and the first number, a third mixed uniformity calculation value is obtained. In step 206, when the third calculated mixing uniformity value is less than or equal to a preset acceptable threshold, it is determined that the mixing uniformity of the single dose of the drug to be tested is acceptable.
[0032] For example, the first number is 10 and the second number is 20. In step 202, the similarity values corresponding to the 30 single doses of drugs to be tested are calculated, and the second average similarity value is obtained. Similarly, step 203 is also for 30 single doses of drugs to be tested.
[0033] In some embodiments, when the third calculated mixing uniformity value is greater than a preset acceptable threshold, it is determined that there is a risk in the mixing uniformity of the single dose of the drug to be tested.
[0034] Take L (acceptable threshold) = 0.06, n = 10 as an example. When the second mixed uniformity calculation value is less than or equal to the preset acceptable threshold, it means that the first mixed uniformity calculation value > 0.06, but the second mixed uniformity calculation value ≤ 0.06. At this time, the calculation is performed again, that is, the retest is performed. The second number is selected during the retest. The second number is greater than the first number. The second number can be 20. If the third mixed uniformity calculation value is ≤ 0.06, the mixing uniformity of the single dose of the drug to be tested is indeed acceptable. If the third mixed uniformity calculation value is less than 0.06, it means that there is indeed a risk in the mixing uniformity of the single dose of the drug to be tested. Through the retest, the credibility of the mixing uniformity results can be compensated and enhanced, the actual situation of the single dose of the drug can be better reflected, and the mixing uniformity of the drug preparation can be more accurately monitored.
[0035] In some embodiments, acceptable standard deviation coefficient values and unacceptable standard deviation coefficient values are obtained by the following method: The acceptable interval of single-dose drug similarity is (0.94, 1), so formula (2) is obtained.
[0036] Formula (2) According to formula (2), it conforms to the one-sided normal distribution. When the acceptance probability is 95%, the upper limit of detection is +1.64S, calculate the maximum relative standard deviation σ 界值 ; Assuming S is the boundary value of σ, for a one-sided test, the confidence interval of σ is [ , ], from which the upper and lower limits of σ are calculated, see Table 2 below.
[0037] Table 2 µ value, σ boundary value, σ lower limit, σ upper limit corresponding to different sample numbers Substitute the lower limit of σ into A = (M- )+kS≤L, the acceptable standard deviation coefficient value, that is, the k value, can be calculated, and the upper limit of σ can be substituted into A=(M- )+kS≤L, the unacceptable standard deviation coefficient value can be calculated, that is, k R Value, so we can get the results corresponding to Table 1.
[0038] In some embodiments, the coefficient value correspondence table includes a correspondence between the number of single doses of the drug to be tested and acceptable standard deviation coefficient values and unacceptable standard deviation coefficient values; the number of single doses of the drug to be tested includes 10, 20 and 30. Different numbers correspond to different standard deviation coefficient values, so that the result of the mixing uniformity of the drug preparation is more accurate. The numbers 10, 20 and 30 are variable and can also be other quantity standards.
[0039] In some embodiments, the analysis method of the acceptable threshold includes: determining the corresponding variety threshold based on the variety of the drug preparation to be tested; and determining the acceptable threshold based on the variety threshold and the threshold conversion relationship.
[0040] In some embodiments, the threshold conversion relationship is: acceptable threshold = 100-variety threshold * 95.
[0041] In some embodiments, if the acceptable phase velocity lower limit is 0.94, the acceptable threshold is generally 0.06. Through the acceptable threshold = 100-variety threshold * 95, the acceptable threshold corresponding to each drug variety can be calculated according to each drug variety, especially for drug varieties with low main drug ingredients and difficult to control processes, the acceptable threshold can be determined more accurately.
[0042] In some embodiments, the analysis method of the variety threshold includes: selecting a third number of single-dose drug sample sets to be tested, calculating the mean similarity of each single-dose drug sample set to be tested; and using the matlab method to analyze the mean similarity of each single-dose drug sample set to be tested to obtain the variety threshold.
[0043] Taking paracetamol tablets, tenofovir disoproxil fumarate tablets and rosuvastatin calcium tablets as examples, the Bootstrap algorithm is used to determine the corresponding variety thresholds. The process is as follows: The Raman spectrum similarity of a batch of drugs is X, (X1, X2, X3…Xn) is a sample from the population X, and the sample mean is used = Estimate the overall mean, n is the total number of single-dose drugs. Assume that the original data of the similarity between the quick-test spectra of a batch of 10 tablets measured by Raman spectrometer and the library spectra are (x1, x2, x3, …, x10).
[0044] For the sample x=(x1,x2,x3,…,x10), use the replacement sampling method to draw a sub-sample x*=(x*1,x*2,x*3,…,x*10) with a capacity of n (n=10).
[0045] Independently draw B (B=10000) subsamples of capacity n (n=10) and calculate the mean (i=1,2,…,B) are arranged in order from small to large. , ,… .
[0046] Take k = [B × α], [B × α] is rounded, α = 0.05. is the lower confidence limit of the approximate one-sided confidence interval of the population mean with a confidence level of 1-α, That is, the Raman spectrum similarity threshold of the batch of drugs (intra-batch similarity) or the drug (inter-batch similarity).
[0047] The variety threshold is obtained using MATLAB method. =a (B×α). The MATLAB method involves the number of random draws, sample statistics and phase velocity matrix in the calculation process. The obtained variety threshold results for paracetamol tablets, tenofovir disoproxil fumarate tablets and rosuvastatin calcium tablets are as follows: Figure 3 As shown, through Figure 3 It can be seen that the discrete degree of the variety thresholds of different varieties is different. The production processes of different varieties and different enterprises of the same variety are different, and there are differences in the control of mixing uniformity. Therefore, if a unified threshold is used for judgment, it may lead to the release standard being too low or the universal threshold being too small, resulting in the release standard being too high.
[0048] The analytical method of this application was used to perform Raman spectroscopy on 614 batches of samples, and the average similarity and standard deviation were calculated. The mixing uniformity was calculated according to formula (1). Among them, the initial test results of 595 batches of samples were acceptable (after k value, or using k value and k R The value was calculated), 19 batches of samples needed to be retested (a second number of single doses of drugs were taken for retesting), and the results were acceptable after testing according to the analytical method of this application. The initial test pass rate was 97%, and the retest pass rate was 100%. Therefore, the test of various different drugs has a high accuracy.
[0049] Acetaminophen tablets, tenofovir disoproxil fumarate tablets and rosuvastatin calcium tablets were taken respectively, and the analysis method of the present application was used to analyze the mixing uniformity. The results are shown in Table 3.
[0050] Table 3. Typical results of mixing uniformity test From Table 3, it can be obtained that the average similarity of paracetamol tablets is high, the sample standard deviation is low, and the value of mixing uniformity is relatively low and acceptable; for tenofovir disoproxil fumarate tablets, the mixing uniformity obtained in the initial test is slightly greater than 0.06, indicating a risk in the initial test. Another 20 tablets were taken, and the average similarity and sample standard deviation of 30 samples were comprehensively calculated, and the mixing uniformity was acceptable; it should be noted that the initial test result of rosuvastatin calcium tablets indicates a risk.
[0051] The Bootstrap algorithm was used to verify the results in Table 3, and the results are shown in Table 4.
[0052] Table 4 Evaluation results of Bootstrap threshold estimation for some varieties As shown in Table 4, it can be obtained that the test conclusion using the Bootstrap algorithm is consistent with the results in Table 3.
[0053] Verification was carried out using the metrological sampling inspection procedure of GB / T 6378.1-2008 / ISO 3951-1:2005. The specific methods include: The single sampling plan for batch-by-batch inspection of a single quality characteristic and a single Acceptable Quality Limit (AQL). Since the σ method requires valid evidence to show that the process standard deviation σ is constant and its value is known, it is not suitable for the detection of mixing uniformity of multiple varieties. Therefore, the standard procedure of the s method was adopted to calculate whether the acceptance criterion of the unilateral specification limit can be met.
[0054] Based on the known sample size n, the given inspection level (usually the general inspection level II), the variety threshold is used as the lower limit acceptable for the variety. The corresponding acceptable constant k is obtained by looking up the table with the unilateral specification limit using AQL.
[0055] According to the metrological sampling inspection procedure of GB / T 6378.1-2008 / ISO 3951-1:2005, calculate Q according to formula (4) L Q L = Formula (4) Among them, Q L : Lower quality statistic; Sample mean, taking the average similarity; L: Acceptable lower limit, taking the variety threshold; s: Standard deviation (S = ) When Q L ≥k, this batch can be accepted. When Q L <k, it is considered that there is a risk. If it is negative, it means that the estimated value of the nonconforming product rate of the process exceeding the specification limit is greater than 0.5, and this part of GB / T6378 always judges it as non-acceptance of the batch.
[0056] QL was calculated according to the above method, and compared with the acceptable constant k of the corresponding sample size and acceptability rate, the results are shown in Table 5.
[0057] Table 5 Evaluation results of measurement sampling inspection procedures After checking the table, when the AQL is 4.0, it is equivalent to an acceptable rate of 96%. When the sample size is 9, the acceptable constant k is 1.159, and when the sample size is 13, the acceptable constant k is 1.189. The QL of acetaminophen tablets is greater than the acceptable constant, and the batch is considered acceptable. The QL of rosuvastatin calcium tablets is less than the acceptable constant, and it is considered that there is a risk in terms of mixing uniformity for this batch. Similarly, when the sample size is 25, the acceptable constant k is 1.225, and when the sample size is 35, the acceptable constant k is 1.311. The QL of tenofovir disoproxil fumarate tablets is greater than the acceptable constant, and the batch is considered acceptable. This conclusion is consistent with the mixing uniformity determination results of this application.
[0058] Therefore, the result of mixing uniformity obtained by the analysis method of the present application is consistent with the conclusion of Bootstrap threshold judgment and the verification conclusion of GB / T6378.1-2008 / ISO 3951-1:2005 measurement sampling inspection procedure, which is credible, simple to operate, and does not require high professional and technical level of operators, meeting the requirements of rapid inspection. It can also be applied to process screening, and by analyzing the mixing uniformity of samples, the process stability of pharmaceutical manufacturers can be effectively monitored. It can also be used to monitor the quality of drugs.
[0059] In some embodiments, the Pearson correlation coefficient is used, that is, the quotient of the covariance and standard deviation between two variables is calculated, and the formula is as follows: Wherein, X is a standard spectrum, and Y is an average spectrum of a first number of rapid test spectra of single-dose drugs to be tested. The first number may be 10.
[0060] According to an embodiment of the present application, a device for analyzing the mixing uniformity of a pharmaceutical preparation is also provided. Figure 4 As shown, the analysis device 400 includes a Raman spectrometer 401 and a processing module 402. The Raman spectrometer 401 is used to collect first Raman spectrum data of each single dose of a first number of single doses of a drug to be tested. The processing module 402 is configured to: Acquire first Raman spectrum data of each single dose of a first number of single doses of a drug to be tested, each single dose of a drug to be tested satisfies a first condition, wherein the first condition includes that each single dose of a drug to be tested belongs to the same drug variety, has the same source, and has the same specification and batch number; Based on the first Raman spectrum data and the standard spectrum data, a similarity value corresponding to each single dose of the drug to be tested is obtained, and a first average similarity value is obtained, wherein the standard spectrum data is the Raman spectrum data of any single dose of the drug to be tested other than the first quantity; Obtaining a first standard deviation based on the first average similarity value and the first Raman spectrum data of each single dose of the drug to be tested; Determining an acceptable standard deviation coefficient value corresponding to the first quantity based on the value of the first quantity and a preset coefficient value correspondence table; Obtaining a first mixed uniformity calculation value based on the first average similarity value, the first standard deviation, and an acceptable standard deviation coefficient value corresponding to the first quantity; When the first calculated mixing uniformity value is less than or equal to a preset acceptable threshold, it is determined that the mixing uniformity of the single dose of the drug to be tested is acceptable.
[0061] There are many types of Raman spectrometers, for example, a Raman spectrometer numbered CEVA3000-0001 can be used for collecting Raman spectrum data of the present application.
[0062] The processor 402 may be a microcontroller unit (MCU), or other general-purpose processors, a digital signal processor (DSP), an application-specific integrated circuit (ASIC), a field-programmable gate array (FPGA), or other programmable logic devices, discrete gate or transistor logic devices, discrete hardware components, etc.
[0063] According to an embodiment of the present application, a non-transitory computer-readable medium is also provided, on which instructions are stored. When executed by a processor, the instructions execute the steps of the method for analyzing the mixing uniformity of a pharmaceutical preparation as described in any embodiment of the present application.
[0064] In addition, although exemplary embodiments have been described herein, the scope includes any and all embodiments based on the present application with equivalent elements, modifications, omissions, combinations (e.g., various embodiments intersecting schemes), adaptations or changes. The elements in the claims are to be interpreted broadly based on the language adopted in the claims, and are not limited to the examples described in this specification or during the practice of this application, and the examples are to be interpreted as non-exclusive. Therefore, this specification and examples are intended to be considered as examples only, and the true scope and spirit are indicated by the following claims and the full scope of their equivalents.
[0065] The above description is intended to be illustrative rather than restrictive. For example, the above examples (or one or more schemes thereof) may be used in combination with each other. For example, a person of ordinary skill in the art may use other embodiments when reading the above description. In addition, in the above-mentioned specific embodiments, various features may be grouped together to simplify the present application. This should not be interpreted as an intention that a feature of an application that does not require protection is necessary for any claim. On the contrary, the subject matter of the present application may be less than all the features of an embodiment of a particular application. Thus, the following claims are incorporated herein in the specific embodiments as examples or embodiments, wherein each claim is independently a separate embodiment, and it is considered that these embodiments may be combined with each other in various combinations or arrangements. The scope of the present invention should be determined with reference to the appended claims and the full scope of equivalent forms granted by these claims.
[0066] The above embodiments are only exemplary embodiments of the present application and are not intended to limit the present invention. The protection scope of the present invention is defined by the claims. Those skilled in the art may make various modifications or equivalent substitutions to the present invention within the essence and protection scope of the present application, and such modifications or equivalent substitutions shall also be deemed to fall within the protection scope of the present invention.
Claims
1. A method for analyzing the mixing uniformity of a pharmaceutical preparation, characterized in that: The analysis method comprises: Acquire first Raman spectrum data of each single dose of a first number of single doses of a drug to be tested, each single dose of a drug to be tested satisfies a first condition, wherein the first condition includes that each single dose of a drug to be tested belongs to the same drug variety, has the same source, and has the same specification and batch number; Based on the first Raman spectrum data and the standard spectrum data, a similarity value corresponding to each single dose of the drug to be tested is obtained, and a first average similarity value is obtained, wherein the standard spectrum data is the Raman spectrum data of any single dose of the drug to be tested other than the first quantity; Obtaining a first standard deviation based on the first average similarity value and the first Raman spectrum data of each single dose of the drug to be tested; Determining an acceptable standard deviation coefficient value corresponding to the first quantity based on the value of the first quantity and a preset coefficient value correspondence table; Obtaining a first mixed uniformity calculation value based on the first average similarity value, the first standard deviation, and an acceptable standard deviation coefficient value corresponding to the first quantity; When the first calculated mixing uniformity value is less than or equal to a preset acceptable threshold, it is determined that the mixing uniformity of the single dose of the drug to be tested is acceptable.
2. The analysis method according to claim 1, characterized in that In the case where the first mixed uniformity calculation value is greater than a preset acceptable threshold, an unacceptable standard deviation coefficient value corresponding to the first quantity is determined based on the numerical value of the first quantity and a preset coefficient value correspondence table; Obtaining a second mixed uniformity calculation value based on the first average similarity value, the first standard deviation, and the unacceptable standard deviation coefficient value; When the second calculated mixing uniformity value is greater than a preset acceptable threshold, it is determined that there is a risk in the mixing uniformity of the single dose of the drug to be tested.
3. The analysis method according to claim 2, characterized in that When the second mixed uniformity calculation value is less than or equal to a preset acceptable threshold, the following steps are performed: Acquire second Raman spectrum data of each single dose of the drug to be tested of a second number of single doses of the drug to be tested, the second number being greater than the first number; Based on the first Raman spectrum data, the second Raman spectrum data and the standard spectrum data, a similarity value corresponding to each single dose of the drug to be tested is obtained, and a second average similarity value is obtained; Obtaining a second standard deviation based on the second average similarity value and the first Raman spectrum data and the second Raman spectrum data of each single dose of the drug to be tested; Determine an acceptable standard deviation coefficient value corresponding to the sum of the second quantity and the first quantity based on the value of the sum of the second quantity and the first quantity and a preset coefficient value correspondence table; Obtaining a third mixed uniformity calculation value based on the second average similarity value, the second standard deviation, and an acceptable standard deviation coefficient value corresponding to the sum of the second number and the first number; When the third calculated mixing uniformity value is less than or equal to a preset acceptable threshold, it is determined that the mixing uniformity of the single dose of the drug to be tested is acceptable.
4. The analysis method according to claim 1, characterized in that Based on the first average similarity value, the first standard deviation and the acceptable standard deviation coefficient value corresponding to the first quantity, a first mixed uniformity calculation value is obtained, including: using formula (1) to calculate the first mixed uniformity calculation value, the formula (1) is: A=(M- )+kS(1) Wherein, A is the calculated value of mixing uniformity; M is the reference value of mixing uniformity; is the average similarity value; k is the acceptable standard deviation coefficient in the initial test; S is the sample standard deviation.
5. The analysis method according to claim 1, characterized in that The coefficient value correspondence table includes the correspondence between the number of single doses of the drug to be tested and the acceptable standard deviation coefficient values and the unacceptable standard deviation coefficient values; the number of single doses of the drug to be tested includes 10, 20 and 30.
6. The analysis method according to claim 1, characterized in that The analysis method of the acceptable threshold value includes: determining the corresponding variety threshold value based on the variety of the drug preparation to be tested; and determining the acceptable threshold value based on the variety threshold value and the threshold conversion relationship.
7. The analysis method according to claim 6, characterized in that The threshold conversion relationship is: acceptable threshold = 100-variety threshold * 95.
8. The analysis method according to claim 6, characterized in that The analysis method of the variety threshold includes: selecting a third number of single-dose drug sample sets to be tested, calculating the mean similarity of each single-dose drug sample set to be tested; and obtaining the variety threshold by analyzing based on the mean similarity of each single-dose drug sample set to be tested using a matlab method.
9. A device for analyzing the mixing uniformity of a pharmaceutical preparation, characterized in that: The analysis device comprises a Raman spectrometer and a processing module, wherein the Raman spectrometer is used to collect first Raman spectrum data of each single dose of a first number of single doses of a drug to be tested; and the processing module is configured to: Acquire first Raman spectrum data of each single dose of a first number of single doses of a drug to be tested, each single dose of a drug to be tested satisfies a first condition, wherein the first condition includes that each single dose of a drug to be tested belongs to the same drug variety, has the same source, and has the same specification and batch number; Based on the first Raman spectrum data and the standard spectrum data, a similarity value corresponding to each single dose of the drug to be tested is obtained, and a first average similarity value is obtained, wherein the standard spectrum data is the Raman spectrum data of any single dose of the drug to be tested other than the first quantity; Obtaining a first standard deviation based on the first average similarity value and the first Raman spectrum data of each single dose of the drug to be tested; Determining an acceptable standard deviation coefficient value corresponding to the first quantity based on the value of the first quantity and a preset coefficient value correspondence table; Obtaining a first mixed uniformity calculation value based on the first average similarity value, the first standard deviation, and an acceptable standard deviation coefficient value corresponding to the first quantity; When the first calculated mixing uniformity value is less than or equal to a preset acceptable threshold, it is determined that the mixing uniformity of the single dose of the drug to be tested is acceptable.
10. A non-transitory computer-readable medium having instructions stored thereon, which, when executed by a processor, execute the steps of the method for analyzing the mixing uniformity of a pharmaceutical preparation according to any one of claims 1 to 8.
